Blood-based biomarkers for early detection of esophageal squamous cell carcinoma

World J Gastroenterol. 2020 Apr 21;26(15):1708-1725. doi: 10.3748/wjg.v26.i15.1708.

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor of the digestive system worldwide, especially in China. Due to the lack of effective early detection methods, ESCC patients often present at an advanced stage at the time of diagnosis, which seriously affects the prognosis of patients. At present, early detection of ESCC mainly depends on invasive and expensive endoscopy and histopathological biopsy. Therefore, there is an unmet need for a non-invasive method to detect ESCC in the early stages. With the emergence of a large class of non-invasive diagnostic tools, serum tumor markers have attracted much attention because of their potential for detection of early tumors. Therefore, the identification of serum tumor markers for early detection of ESCC is undoubtedly one of the most effective ways to achieve early diagnosis and treatment of ESCC. This article reviews the recent advances in the discovery of blood-based ESCC biomarkers, and discusses the origins, clinical applications, and technical challenges of clinical validation of various types of biomarkers.

Keywords: Autoantibodies; Biomarker; Blood-based; Diagnosis; Esophageal squamous cell carcinoma; MicroRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Early Detection of Cancer / methods*
  • Esophageal Neoplasms / blood
  • Esophageal Neoplasms / diagnosis*
  • Esophageal Neoplasms / mortality
  • Esophageal Squamous Cell Carcinoma / blood
  • Esophageal Squamous Cell Carcinoma / diagnosis*
  • Esophageal Squamous Cell Carcinoma / mortality
  • Humans
  • Prognosis
  • ROC Curve

Substances

  • Biomarkers, Tumor